Horner Syndrome: Overview, Anatomy, Pathophysiology (original) (raw)

Overview

Overview

Horner syndrome (Horner’s syndrome or oculosympathetic paresis) results from an interruption of the sympathetic nerve supply to the eye and is characterized by the classic triad of miosis (ie, constricted pupil), partial ptosis, and loss of hemifacial sweating (ie, anhidrosis), as well as enophthalmos (sinking of the eyeball into the bony cavity that protects the eye). The term Horner syndrome is commonly used in English-speaking countries, whereas the term Bernard-Horner syndrome is common in France. Von Passow syndrome is an association of Horner syndrome with iris heterochromia (heterochromia iridis). [1, 2]

Causes of Horner syndrome include the following:

Horner syndrome is uncommon. No age, sexual, or racial predilections are known to exist. The prognosis and the complications to be expected depend on the underlying cause of the syndrome, as does treatment.

eMedicine Logo

Anatomy

Sympathetic innervation to the eye consists of a 3-neuron arc. First-order central sympathetic fibers arise from the posterolateral hypothalamus, descend uncrossed through the midbrain and pons, and terminate in the intermediolateral cell column of the spinal cord at the level of C8-T2 (ciliospinal center of Budge). Second-order preganglionic pupillomotor fibers exit the spinal cord at the level of T1 and enter the cervical sympathetic chain, where they are in close proximity to the pulmonary apex and the subclavian artery.

The fibers ascend through the sympathetic chain and synapse in the superior cervical ganglion at the level of the bifurcation of the common carotid artery (C3-C4). Postganglionic pupillomotor fibers exit the superior cervical ganglion and ascend along the internal carotid artery. Shortly after the postganglionic fibers leave the superior cervical ganglion, vasomotor and sudomotor fibers branch off, traveling along the external carotid artery to innervate the blood vessels and sweat glands of the face.

The third-order pupillomotor fibers ascending along the internal carotid artery enter the cavernous sinus. The fibers then leave the carotid plexus briefly to join the abducens nerve (cranial nerve [CN] VI) in the cavernous sinus and enter the orbit through the superior orbital fissure along with the ophthalmic branch (V1) of the trigeminal nerve (CN V) via the long ciliary nerves. The long ciliary nerves then innervate the iris dilator and the Müller muscle. [1]

eMedicine Logo

Pathophysiology

Horner syndrome may develop from lesions at any point along the sympathetic pathway. [7] Abnormalities found in all patients, regardless of the level of interruption, include the following:

Depending on the level of the lesion, impaired flushing and sweating may be found ipsilaterally. With central first-order neuron lesions, anhidrosis affects the ipsilateral side of the body. Lesions affecting second-order neurons may cause anhidrosis of the ipsilateral face. With postganglionic lesions occurring after vasomotor and sudomotor fibers have branched off the sympathetic chain, anhidrosis is either absent or limited to an area above the ipsilateral brow. The pupils react normally to light and accommodation.

Iris heterochromia (with the affected eye being hypopigmented) is seen in congenital Horner syndrome or Horner syndrome that occurs in children younger than 2 years. Iris heterochromia also may occur in long-standing Horner syndrome. [1]

eMedicine Logo

Epidemiology

Horner syndrome has a frequency of 1 per 6,250 population. It may occur at any age and in any ethnicity. [8]

eMedicine Logo

Etiology of Horner Syndrome

Horner syndrome can be congenital, acquired, or purely hereditary (autosomal dominant). The interruption of the sympathetic fibers may occur centrally (ie, between the hypothalamus and the fibers’ point of exit from the spinal cord [C8 to T2]) or peripherally (ie, in cervical sympathetic chain, at the superior cervical ganglion, or along the carotid artery). [1, 9]

The common lesions that cause Horner syndrome interfere with preganglionic fibers as they course through the upper thorax. Virtually all lesions producing postganglionic sympathetic dysfunction are located intracranially or intraorbitally because the superior cervical ganglion is near the skull. Preganglionic Horner syndrome indicates a serious underlying pathology and is associated with a high incidence of malignancy. Postganglionic involvement has primarily benign causes (ie, usually a vascular headache). [1]

Causes of Horner syndrome may also be classified as involving first-order, second-order, or third-order neuron lesions. First-order neuron lesions that may give rise to the syndrome include the following:

Second-order neuron lesions that may give rise to Horner syndrome include the following [1] :

Third-order neuron lesions that may give rise to Horner syndrome include the following [1] :

eMedicine Logo

Clinical Presentation

Patient history

Obtaining a careful history is very helpful in the localization of lesions causing Horner syndrome. The symptoms reported by the patient will depend on the underlying cause, as follows [1] :

Although Horner syndrome is commonly an incidental finding related to a benign cause, it occasionally may be a manifestation of a serious and life-threatening disorder. Careful direction of the history to rule out such life-threatening disorders is vital.

Given that malignancy is a prominent feature of recently diagnosed preganglionic Horner syndrome, patients may avoid an unnecessary extensive workup for carcinoma if the lesion can be shown to be old or long-standing. To prove that a lesion is long-standing, inspect old photographs of the patient that might show ptosis or anisocoria. If the affected iris is blue and the other is brown, the lesion most likely was present at birth or during the first 2 years of life. (Of course, this color asymmetry will not occur in patients who are genetically blue-eyed.)

It is important to determine whether the patient has recently undergone an interventional procedure that has the potential to cause relevant neurologic damage. Iatrogenic Horner syndrome has been reported as a complication of a variety of chest, neck, and otolaryngologic procedures [16, 17, 18, 19, 20] ; for example, ptosis may rarely complicate injection of botulinum toxin for glabellar lines. [21]

Patients may not be able to open the affected eye completely and may not sweat on that side of the face. The presence, absence, or location of anhidrosis is an important localizing sign.

Patients with preganglionic lesions may have facial flushing. This symptom (ie, harlequin effect) occurs with physical exercise in some patients. Patients with postganglionic lesions may have ipsilateral orbital pain or a migrainelike headache.

Raeder described a combination of orbital pain, miosis, and ptosis and termed it paratrigeminal syndrome. [22] If this set of symptoms is associated with lesions of CNs III-VI on the ipsilateral side, a mass lesion in the middle cranial fossa (ie, type I Raeder paratrigeminal syndrome) should be suspected. A benign form characterized by episodic retrobulbar or orbital pain, with miosis and ptosis but without associated cranial nerve findings, is considered a migraine variant (ie, type II Raeder paratrigeminal syndrome).

Patients with carotid artery dissection may present with ipsilateral head, neck, or facial pain.

Physical examination

Important aspects of the physical examination include the following:

The pupil on the affected side may be round and constricted (ie, miosis). In individuals with Horner syndrome, the anisocoria is greater in darkness than in light. The affected pupil dilates more slowly than the normal pupil does because the affected pupil lacks the pull of the dilator muscle (ie, dilation lag). Patients may have a loss of the ciliospinal reflex (ie, afferent C2, C3), in which the pupil fails to dilate when the skin on back of the neck is pinched. (Most authors, however, consider this finding unreliable.)

Patients have dry skin (ie, anhidrosis) on the same side of their face as the affected pupil. The pattern of a patient’s inability to sweat may be helpful in localizing the lesion. If a patient has a lesion in the area of the common carotid artery, loss of sweating involves the entire side of the face. With lesions distal to the carotid bifurcation, the lack of sweating is confined to the medial aspect of the forehead and the side of the nose.

Other findings that may be noted include the following:

eMedicine Logo

Differential Diagnosis

Horner syndrome in the presence of pain merits special consideration.

Horner syndrome in the presence of axial, shoulder, scapula, arm, or hand pain may be indicative of compression by an apical lung tumor (Pancoast tumor).

Horner syndrome in the presence of acute-onset, ipsilateral facial or neck pain may indicate carotid artery dissection, which may be caused by cardiovascular disease, arteriopathy (eg, fibromuscular dysplasia or collagen disorders), or trauma (even minor trauma, such as results from quick head turns). If carotid artery dissection is suspected, especially if there are signs or symptoms of retinal ischemia, urgent neuroimaging studies (magnetic resonance imaging or magnetic resonance angiography) should be obtained along with neurologic consultation.

Postganglionic Horner syndrome associated with ipsilateral headache has several causes. Patients with spontaneous carotid artery dissection may present with Horner syndrome and ipsilateral headache. Patients with cluster headaches may develop ipsilateral Horner syndrome during an acute attack.

The term Raeder paratrigeminal syndrome is applied to patients, usually middle-aged males, who have Horner syndrome and daily unilateral head pain. In the original Raeder syndrome, the pain is trigeminal pain associated with hypoesthesia or anesthesia in the distribution of the trigeminal nerve (cranial nerve [CN] V). Pain related to Raeder syndrome can be distinguished from that related to cluster headaches or carotid disease in that the latter conditions occur without impairment of trigeminal nerve function.

Horner syndrome may be the first manifestation of neuroblastoma.

Conditions to be considered in the differential diagnoses include the following:

Unilateral use of miotic drugs or mydriatic drugs should also be considered in the differential diagnoses. Other medications to consider include local anesthetics (lidocaine, bupivacaine, etidocaine), acetophenazine, alseroxylon, butaperazine, carphenazine, chloroprocaine, chlorpromazine, deserpidine, diacetylmorphine, diethazine, ethopropazine, fluphenazine, guanethidine, influenza virus vaccine, levodopa, lidocaine, mesoridazine, methdilazine, methotrimeprazine, oral contraceptives, perazine, prilocaine, procaine, prochlorperazine, promazine, promethazine, propoxycaine, reserpine, thioproperazine, thioridazine, and trifluoperazine.

eMedicine Logo

Laboratory Studies

In general, laboratory studies do not play a significant role in the diagnosis and management of Horner syndrome. However, depending on the localization and suspected etiology, certain laboratory tests may be considered, as follows [1] :

eMedicine Logo

Imaging Studies

Imaging studies may be ordered in conjunction with appropriate medical or surgical consultation, depending on the localization and suspected etiology. [1, 23]

A chest radiograph should be obtained; apical bronchogenic carcinoma is the most common cause of Horner syndrome. If stroke is suspected, computed tomography (CT) of the head should be performed.

Painful Horner syndrome should alert the physician to the possibility of carotid artery dissection, and the patient should undergo further testing (ie, magnetic resonance imaging [MRI]/magnetic resonance angiography [MRA] of the brain and neck) to exclude this possibility. Internal carotid artery dissection is life-threatening and carries a risk that the patient will experience a disabling stroke.

Ultrasonography may be considered but has not been found to be reliable for diagnosing carotid artery dissection in patients with isolated Horner syndrome. [24]

MIBG Scan is a nuclear imaging test to asist in the diagnosis and assessment of neuroendocrine tumors. [25]

eMedicine Logo

Pharmacologic Testing

Pharmacologic testing is very helpful in the diagnosis of Horner syndrome. [1, 26] The following pharmacologic tests document the presence or absence of an ocular sympathetic lesion and identify the level of involvement (ie, preganglionic or postganglionic). Localizing the lesion is important because preganglionic lesions are associated with a higher incidence of malignancy that necessitates extensive investigations.

Topical cocaine test

The basis for the topical cocaine test is the ability of cocaine to act as an indirect sympathomimetic agent by inhibiting the reuptake of norepinephrine from the synaptic cleft at the nerve ending.

The test is performed by instilling cocaine solution (2-4% or, according to some, 4-10%) into each eye. Cocaine instilled in an eye with intact sympathetic innervation causes the pupil to dilate. A sympathetically denervated pupil (such as is present in Horner syndrome) dilates poorly to cocaine, regardless of the level of the sympathetic interruption, because of the absence of endogenous norepinephrine in the synapse.

For optimal accuracy, test results should be evaluated 30 minutes or longer after cocaine is administered. The maximal response is seen 40-60 minutes after instillation of the drops. Postcocaine anisocoria greater than 0.8 mm is sufficient to diagnose Horner syndrome.

The disadvantages of the topical cocaine test are as follows:

Topical apraclonidine test

The topical apraclonidine test is a practical and reliable alternative to the topical cocaine test; it is readily available and adequately sensitive (87%) and is currently the test of choice. [27, 28, 29]

Apraclonidine is an ocular hypotensive agent that acts as a weak alpha1-agonist and a strong alpha2-agonist. [30, 27, 26, 31] Typically given in a 0.5% or 1% solution, it has little to no effect on a normal pupil but has a mydriatic effect on an abnormal pupil.

In Horner syndrome, upregulation of alpha1-receptors increases apraclonidine sensitivity and causes denervation supersensitivity of the iris dilator muscle. The denervation supersensitivity results in pupillary dilatation and lid elevation on the abnormal side but no response or mild miosis on the normal side from alpha2-activity after apraclonidine administration. Reversal of anisocoria occurs after bilateral instillation of apraclonidine.

In acute cases, false-negative test results may occur because the alpha1-receptor upregulation on which the effect of apraclonidine depends may take 5-8 days. [32, 33] Accordingly, a negative apraclonidine test result, especially in acute settings, does not exclude Horner syndrome. In such cases, a cocaine test should be performed to exclude Horner syndrome.

Apraclonidine 0.5% or 1% may cause lethargy, bradycardia, and respiratory depression in infants younger than 6 months as a consequence of the immaturity of the blood-brain barrier. [34]

Topical hydroxyamphetamine test

The localization of a lesion causing Horner syndrome may be aided by the use of the topical hydroxyamphetamine test. Hydroxyamphetamine stimulates the release of stored endogenous norepinephrine from the postganglionic axon terminals into the neuromuscular junction at the iris dilator muscles. This test may distinguish a postganglionic third-order neuron lesion from a presynaptic second-order or first-order neuron lesion.

To perform the test, 2 drops of 1% hydroxyamphetamine solution are instilled into each eye. A period of 24-48 hours must be allowed to elapse between the cocaine test and the hydroxyamphetamine test because cocaine has the ability to inhibit the uptake of hydroxyamphetamine into the presynaptic vesicles, thereby reducing the accuracy of the latter test.

Hydroxyamphetamine drops instilled into an eye with Horner syndrome with intact postganglionic fibers (ie, first- or second-order neuron lesions) dilate the affected pupil to an equal or greater extent than they do the normal pupil. However, hydroxyamphetamine drops instilled into an eye with Horner syndrome with damaged postganglionic fibers (ie, third-order neuron lesions) do not dilate the affected pupil as well as they do the normal pupil.

eMedicine Logo

Treatment of Horner Syndrome

In general, appropriate treatment of Horner syndrome depends on the underlying cause. The goal of treatment is to eradicate the underlying disease process. In many cases, however, no effective treatment is known. Prompt recognition of the syndrome and expedient referral to appropriate specialists are vital. [1]

Whether surgical care is indicated and what type is appropriate depend on the particular cause of Horner syndrome. Potential surgical interventions include neurosurgical care for aneurysm-related Horner syndrome and vascular surgical care for causative conditions such as carotid artery dissection or aneurysm.

For optimal management of the underlying cause, the following specialist consultations may be required:

eMedicine Logo

Questions & Answers

  1. Khan Z, Bollu PC. Horner Syndrome. StatPearls. 2022 Jan. [QxMD MEDLINE Link]. [Full Text].
  2. von Passow A. Okulare Paresen im Symptomenbilde des "Status dysraphicus", zugleich ein Beitrag zur Ätiologie der Sympathikusparese (Horner-Syndrom und Heterochromia iridis). Münchener Medizinische Wochenshrift. 1934. 74:1243-9.
  3. Krasnianski M, Georgiadis D, Grehl H, Lindner A. [Correlation of clinical and magnetic resonance imaging findings in patients with brainstem infarction]. Fortschr Neurol Psychiatr. 2001 May. 69(5):236-41. [QxMD MEDLINE Link].
  4. Biousse V, Touboul PJ, D'Anglejan-Chatillon J, Lévy C, Schaison M, Bousser MG. Ophthalmologic manifestations of internal carotid artery dissection. Am J Ophthalmol. 1998 Oct. 126(4):565-77. [QxMD MEDLINE Link].
  5. Zou ZY, Yao YT. Horner Syndrome Caused by Internal Jugular Vein Catheterization. J Cardiothorac Vasc Anesth. 2020 Jun. 34 (6):1636-1640. [QxMD MEDLINE Link].
  6. Chambers DJ, Bhatia K. Horner's syndrome following obstetric neuraxial blockade - a systematic review of the literature. Int J Obstet Anesth. 2018 Aug. 35:75-87. [QxMD MEDLINE Link].
  7. Reede DL, Garcon E, Smoker WR, Kardon R. Horner's syndrome: clinical and radiographic evaluation. Neuroimaging Clin N Am. 2008 May. 18(2):369-85, xi. [QxMD MEDLINE Link].
  8. Smith SJ, Diehl N, Leavitt JA, Mohney BG. Incidence of pediatric Horner syndrome and the risk of neuroblastoma: a population-based study. Arch Ophthalmol. 2010 Mar. 128 (3):324-9. [QxMD MEDLINE Link].
  9. Lyrer PA, Brandt T, Metso TM, Metso AJ, Kloss M, Debette S, et al. Clinical import of Horner syndrome in internal carotid and vertebral artery dissection. Neurology. 2014 May 6. 82(18):1653-9. [QxMD MEDLINE Link].
  10. Jadon A. Horner's syndrome and weakness of upper limb after epidural anaesthesia for caesarean section. Indian J Anaesth. 2014 Jul. 58(4):464-6. [QxMD MEDLINE Link]. [Full Text].
  11. Ying X, Dandan G, Bin C. Postoperative Horner's syndrome after video-assisted thyroidectomy: a report of two cases. World J Surg Oncol. 2013 Dec 30. 11:315. [QxMD MEDLINE Link]. [Full Text].
  12. Kucur C, Ozbay I, Oghan F, Yildirim N, Zeybek Sivas Z, Canbaz Kabay S. A Rare Complication of Radiofrequency Tonsil Ablation: Horner Syndrome. Case Rep Otolaryngol. 2015. 2015:570520. [QxMD MEDLINE Link].
  13. Foss-Skiftesvik J, Hougaard MG, Larsen VA, Hansen K. Clinical Reasoning: Partial Horner syndrome and upper right limb symptoms following chiropractic manipulation. Neurology. 2015 May 26. 84 (21):e175-80. [QxMD MEDLINE Link].
  14. Smith SJ, Diehl N, Leavitt JA, Mohney BG. Incidence of pediatric Horner syndrome and the risk of neuroblastoma: a population-based study. Arch Ophthalmol. 2010 Mar. 128(3):324-9. [QxMD MEDLINE Link].
  15. Pirouzian A, Holz HA, Ip KC, Sudesh R. Acquired infantile Horner syndrome and spontaneous internal carotid artery dissection: a case report and review of literature. J AAPOS. 2010 Apr. 14(2):172-4. [QxMD MEDLINE Link].
  16. Piccoli M, Golinelli M, Colli G, Mullineris B, Melotti G. Homer syndrome after thoracoscopic apicectomy for spontaneous pneumothorax as a complication of chest tube placement. Chir Ital. 2007 Nov-Dec. 59(6):887-9. [QxMD MEDLINE Link].
  17. González Martín-Moro J, Sastre-Pérez J, Pena Fernández I. Horner syndrome after temporomandibular joint arthroscopy: a new complication. J Oral Maxillofac Surg. 2009 Jun. 67(6):1320-2. [QxMD MEDLINE Link].
  18. Allen AY, Meyer DR. Neck procedures resulting in Horner syndrome. Ophthal Plast Reconstr Surg. 2009 Jan-Feb. 25(1):16-8. [QxMD MEDLINE Link].
  19. Rombolá CA, León Atance P, Honguero Martínez AF. [Claude Bernard-Horner syndrome as a rare complication of postoperative pleural drainage]. Arch Bronconeumol. 2008 Feb. 44(2):116-7. [QxMD MEDLINE Link].
  20. González-Aguado R, Morales-Angulo C, Obeso-Agüera S, Longarela-Herrero Y, García-Zornoza R, Acle Cervera L. Horner's syndrome after neck surgery. Acta Otorrinolaringol Esp. 2012 Jul-Aug. 63(4):299-302. [QxMD MEDLINE Link].
  21. Monheit GD, Cohen JL. Long-term safety of repeated administrations of a new formulation of botulinum toxin type A in the treatment of glabellar lines: interim analysis from an open-label extension study. J Am Acad Dermatol. 2009 Sep. 61(3):421-5. [QxMD MEDLINE Link].
  22. Raeder JG. Brain. Oxford: 1924. 47: 149-158.
  23. Almog Y, Gepstein R, Kesler A. Diagnostic value of imaging in horner syndrome in adults. J Neuroophthalmol. 2010 Mar. 30(1):7-11. [QxMD MEDLINE Link].
  24. Arnold M, Baumgartner RW, Stapf C, Nedeltchev K, Buffon F, Benninger D, et al. Ultrasound diagnosis of spontaneous carotid dissection with isolated Horner syndrome. Stroke. 2008 Jan. 39(1):82-6. [QxMD MEDLINE Link]. [Full Text].
  25. Bhate M, Flaherty M, Rowe N, Howman-Giles R. Paediatric Horner Syndrome: How much further to investigate?. Indian J Ophthalmol. 2020 Nov. 68 (11):2607-2610. [QxMD MEDLINE Link].
  26. Mughal M, Longmuir R. Current pharmacologic testing for Horner syndrome. Curr Neurol Neurosci Rep. 2009 Sep. 9(5):384-9. [QxMD MEDLINE Link].
  27. Koc F, Kavuncu S, Kansu T, Acaroglu G, Firat E. The sensitivity and specificity of 0.5% apraclonidine in the diagnosis of oculosympathetic paresis. Br J Ophthalmol. 2005 Nov. 89(11):1442-4. [QxMD MEDLINE Link]. [Full Text].
  28. Pérez-Iñigo MA, González I, Fernández FJ, Díaz S, Ferrer C, Alias E, et al. [Usefulness of apraclonidine in the diagnosis of Horner syndrome]. Arch Soc Esp Oftalmol. 2009 Feb. 84(2):105-8. [QxMD MEDLINE Link].
  29. Freedman KA, Brown SM. Topical apraclonidine in the diagnosis of suspected Horner syndrome. J Neuroophthalmol. 2005 Jun. 25(2):83-5. [QxMD MEDLINE Link].
  30. Morales J, Brown SM, Abdul-Rahim AS, Crosson CE. Ocular effects of apraclonidine in Horner syndrome. Arch Ophthalmol. 2000 Jul. 118(7):951-4. [QxMD MEDLINE Link].
  31. Cooper-Knock J, Pepper I, Hodgson T, Sharrack B. Early diagnosis of Horner syndrome using topical apraclonidine. J Neuroophthalmol. 2011 Sep. 31(3):214-6. [QxMD MEDLINE Link].
  32. Kawasaki A, Borruat FX. False negative apraclonidine test in two patients with Horner syndrome. Klin Monbl Augenheilkd. 2008 May. 225(5):520-2. [QxMD MEDLINE Link].
  33. Dewan MA, Harrison AR, Lee MS. False-negative apraclonidine testing in acute Horner syndrome. Can J Ophthalmol. 2009 Feb. 44(1):109-10. [QxMD MEDLINE Link].
  34. Watts P, Satterfield D, Lim MK. Adverse effects of apraclonidine used in the diagnosis of Horner syndrome in infants. J AAPOS. 2007 Jun. 11(3):282-3. [QxMD MEDLINE Link].

Previous

Next

Author

Christopher M Bardorf, MD, MS Ophthalmologist, Children's Eye Physicians

Christopher M Bardorf, MD, MS is a member of the following medical societies: American Medical Association

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

J James Rowsey, MD Former Director of Corneal Services, St Luke's Cataract and Laser Institute

J James Rowsey, MD is a member of the following medical societies: American Academy of Ophthalmology, American Association for the Advancement of Science, American Medical Association, Association for Research in Vision and Ophthalmology, Florida Medical Association, Sigma Xi, The Scientific Research Honor Society, Southern Medical Association, Pan-American Association of Ophthalmology

Disclosure: Nothing to disclose.

Chief Editor

Edsel B Ing, MD, PhD, MBA, MEd, MPH, MA, FRCSC Professor, Department of Ophthalmology and Vision Sciences, Sunnybrook Hospital, University of Toronto Faculty of Medicine; Incoming Chair of Ophthalmology, University of Alberta Faculty of Medicine and Dentistry, Canada

Edsel B Ing, MD, PhD, MBA, MEd, MPH, MA, FRCSC is a member of the following medical societies: American Academy of Ophthalmology, American Association for Pediatric Ophthalmology and Strabismus, American Society of Ophthalmic Plastic and Reconstructive Surgery, Canadian Medical Association, Canadian Ophthalmological Society, Canadian Society of Oculoplastic Surgery, Chinese Canadian Medical Society, European Society of Ophthalmic Plastic and Reconstructive Surgery, North American Neuro-Ophthalmology Society, Ontario Medical Association, Royal College of Physicians and Surgeons of Canada, Statistical Society of Canada

Disclosure: Nothing to disclose.

Additional Contributors

Enrique Garcia-Valenzuela, MD, PhD Clinical Assistant Professor, Department of Ophthalmology, University of Illinois Eye and Ear Infirmary; Consulting Staff, Vitreo-Retinal Surgery, Midwest Retina Consultants, SC, Parkside Center

Enrique Garcia-Valenzuela, MD, PhD is a member of the following medical societies: American Academy of Ophthalmology, American Society of Retina Specialists, Association for Research in Vision and Ophthalmology, Retina Society, Society for Neuroscience

Disclosure: Nothing to disclose.

Acknowledgements

Gerhard W Cibis, MD Clinical Professor, Director of Pediatric Ophthalmology Service, Department of Ophthalmology, University of Kansas School of Medicine

Gerhard W Cibis, MD is a member of the following medical societies: American Academy of Ophthalmology, American Association for Pediatric Ophthalmology and Strabismus, and American Ophthalmological Society

Disclosure: Nothing to disclose.

Jules E Harris, MD Clinical Professor of Medicine, Section of Hematology/Oncology, University of Arizona College of Medicine, Arizona Cancer Center

Jules E Harris, MD is a member of the following medical societies: American Association for Cancer Research, American Association for the Advancement of Science, American Association of Immunologists, American Society of Hematology, and Central Society for Clinical Research

Disclosure: GlobeImmune Salary Consulting

Malvinder S Parmar, MB, MS, FRCP(C), FACP Assistant Professor (VPT), Faculty of Medicine, University of Ottawa Faculty of Medicine; Associate Professor, Department of Internal Medicine, Northern Ontario School of Medicine; Consulting Physician, Timmins and District Hospital, Ontario, Canada

Malvinder S Parmar, MB, MS, FRCP(C), FACP is a member of the following medical societies: American College of Physicians, American Society of Nephrology, Canadian Medical Association, Ontario Medical Association, and Royal College of Physicians and Surgeons of Canada

Disclosure: Nothing to disclose.

J James Rowsey, MD Former Director of Corneal Services, St Luke's Cataract and Laser Institute

J James Rowsey, MD is a member of the following medical societies: American Academy of Ophthalmology, American Association for the Advancement of Science, American Medical Association, Association for Research in Vision and Ophthalmology, Florida Medical Association, Pan-American Association of Ophthalmology, Sigma Xi, and Southern Medical Association

Disclosure: Nothing to disclose.

Philip Schulman, MD Chief, Medical Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center; Clinical Professor, Department of Medicine, New York University School of Medicine

Philip Schulman, MD is a member of the following medical societies: American Association for Cancer Research, American College of Physicians, American Society of Hematology, and Medical Society of the State of New York

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment